Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: Using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey

International Journal of Urology

Volumn 13, Issue 9, 2006, Pages 1202-1206

  Suzuki, Hiroyoshi ^a,b   Yano, Masashi ^a,b   Awa, Yusuke ^a,b   Nakatsu, Hiroomi ^b   Egoshi, Ken Ichi ^b   Mikami, Kazuo ^b   Ota, Sho ^b   Okano, Tatsuya ^b   Hamano, Satoru ^b   Ohki, Takemasa ^b   Furuya, Yuzo ^b   Ichikawa, Tomohiko ^a,b  

^a CHIBA UNIVERSITY   (Japan)

^b Chiba Continence Research Society   (Japan)

Author keywords

1 blocker; Benign prostatic hyperplasia; I PSS; Quality of life; SF 36 health survey

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; TAMSULOSIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; FUNCTIONAL ASSESSMENT; HEALTH SURVEY; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MENTAL HEALTH; ORGAN SIZE; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; QUALITY OF LIFE; QUESTIONNAIRE; RESIDUAL URINE; SCORING SYSTEM; SEX DIFFERENCE; SHORT FORM 36; SOCIAL STATUS; SYMPTOM; TREATMENT DURATION; URETHRITIS; URINE FLOW RATE;

AGED; ANTINEOPLASTIC AGENTS; HEALTH STATUS INDICATORS; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; QUESTIONNAIRES; SULFONAMIDES; TREATMENT OUTCOME; URINARY RETENTION;

EID: 33748772231     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2006.01594.x     Document Type: Article

References (17)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J. Urol. 1984; 132: 474-9.
2. Haltbakk J, Hanestad BR, Hunskaar S. Use and misuse of the concept of quality of life in evaluating surgical treatments for lower urinary tract symptoms. BJU Int. 2003; 91: 380-8.
3. Djavan B. Lower urinary tract symptoms/benign prostatic hyperplasia: fast control of the patients'quality of life. Urology 2003; 62 (Suppl. 3A): 6-14.
4. O'Leary MP. Lower urinary tract symptoms/benign prostatic hyperplasia: maintaining symptom control and reducing complications. Urology 2003; 62 (Suppl. 3A): 15-23.
5. Wilt TJ, MacDonald R, Nelson D. Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. J. Urol. 2002; 167: 177-83.
6. Lyseng-Williamson KA, Jarvis B, Wagstaff AJ. Tamsulosin: an update of its role in the management of lower urinary tract symptoms. Drugs 2002; 62: 135-67.
7. Ichioka K, Ohara H, Terada N et al. Long-term treatment outcome of tamsulosin for benign prostatic hyperplasia. Int. J. Urol. 2004; 11: 870-5.
8. Schulman CC, Cortvriend J, Jonas U, Lock TM, Vaage S, Speakman MJ. Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. Eur. Urol. 1999; 36: 609-20.
9. Schulman CC, Lock TM, Buzelin JM et al. Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia. J. Urol. 2001; 166: 1358-63.
10. O'Sullivan MJ, Murphy C, Deasy C, Iohom G, Kiely EA, Shorten G. Effects of transurethral resection of prostate on the quality of life of patients with benign prostatic hyperplasia. J. Am. Coll. Surg. 2004; 198: 394-403.
11. Barry MJ, Fowler FJ Jr, O'Leary MP et al. The American Urological Association symptom index for benign prostatic hyperplasia. J. Urol. 1992; 148: 1549-57.
12. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care 1992; 30: 473-83.
13. Suzuki H, Akakura K, Igarashi T et al. Clinical usefulness of serum anti-p53 antibodies for prostate cancer detection: a comparative study with PSA parameters. J. Urol. 2004; 171: 182-6.
14. Suzuki H, Komiya A, Kamiya N et al. Development of a nomogram to predict probability of positive initial prostate biopsy among Japanese patients. Urology 2006; 67: 131-6.
15. Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K. Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J. Clin. Epidemiol. 1998; 51: 1037-44.
16. Ishihara M, Suzuki H, Akakura K et al. Baseline health-related quality of life in the management of prostate cancer. Int. J. Urol. 2006; 13: 920-25.
17. Tubaro A, La Vecchi C. The relation of lower urinary tract symptoms with life-style factors and objective measures of benign prostatic enlargement and obstruction: an Italian survey. Eur. Urol. 2004; 45: 767-72.